scispace - formally typeset
F

Funda Meric-Bernstam

Researcher at University of Texas MD Anderson Cancer Center

Publications -  892
Citations -  48065

Funda Meric-Bernstam is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 96, co-authored 753 publications receiving 36803 citations. Previous affiliations of Funda Meric-Bernstam include Mayo Clinic & Medical University of Graz.

Papers
More filters
Journal ArticleDOI

Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children

TL;DR: Larotrectinib had marked and durable antitumor activity in patients with TRK fusion–positive cancer, regardless of the age of the patient or of the tumor type.
Journal ArticleDOI

Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer.

Katherine A Hoadley, +738 more
- 05 Apr 2018 - 
TL;DR: Molecular similarities among histologically or anatomically related cancer types provide a basis for focused pan-cancer analyses, such as pan-gastrointestinal, Pan-gynecological, pan-kidney, and pan-squamous cancers, and those related by stemness features, which may inform strategies for future therapeutic development.
Journal ArticleDOI

Clonal evolution in breast cancer revealed by single nucleus genome sequencing

TL;DR: The data show that aneuploid rearrangements occurred early in tumour evolution and remained highly stable as the tumour masses clonally expanded, which has important implications for the diagnosis, therapeutic treatment and evolution of chemoresistance in breast cancer.
Journal ArticleDOI

PD-L1 Expression in Triple-Negative Breast Cancer

TL;DR: Using tissue microarrays containing 105 triple-negative breast cancer specimens, Mittendorf and colleagues show that 20% of the TNBC specimens express PD-L1, half have lost PTEN, and inhibitors of PI3K pathway decrease PD- l1 expression, providing a rationale for therapeutic targeting of PD- L1 for TNBC.
Journal ArticleDOI

KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors.

TL;DR: Sotorasib showed encouraging anticancer activity in patients with heavily pretreated advanced solid tumors harboring the KRAS p.G12C mutation and responded to pharmacokinetics and objective response according to Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1.